Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Rare Malignant Solid Neoplasm”

22 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 22 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07307053
What this trial is testing

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

Who this might be right for
Rare Malignant NeoplasmAdvanced Solid TumorsMetastatic Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 600
Not applicableStudy completedNCT00898079
What this trial is testing

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Who this might be right for
Acute Undifferentiated LeukemiaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChildhood Acute Lymphoblastic Leukemia+11 more
Children's Oncology Group 2,545
Large-scale testing (Phase 3)Looking for participantsNCT07440290
What this trial is testing

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

Who this might be right for
Haematological MalignancyMalignant NeoplasmLymphoproliferative Disorders+17 more
Cancer Research UK 30
Large-scale testing (Phase 3)Looking for participantsNCT05770037
What this trial is testing

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

Who this might be right for
Haematological MalignancyMalignant NeoplasmLymphoproliferative Disorders+8 more
Cancer Research UK 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04969887
What this trial is testing

Combination Immunotherapy in Rare Cancers Under InvesTigation

Who this might be right for
Advanced Biliary Tract CancerNeuroendocrine TumorsFemale Reproductive System Neoplasm+1 more
Olivia Newton-John Cancer Research Institute 240
Testing effectiveness (Phase 2)Active Not RecruitingNCT05142241
What this trial is testing

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

Who this might be right for
Malignant Solid Neoplasm
National Cancer Institute (NCI) 14
Not applicableLooking for participantsNCT04151342
What this trial is testing

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Who this might be right for
CancerMalignancies MultipleMalignant Solid Tumor+7 more
University Health Network, Toronto 5,500
Not applicableLooking for participantsNCT03739827
What this trial is testing

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Who this might be right for
Malignant Solid TumorsOther Neoplasms Solid TumorsPediatric Solid Tumor+2 more
National Cancer Institute (NCI) 10,000
Large-scale testing (Phase 3)Looking for participantsNCT05768178
What this trial is testing

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Who this might be right for
Haematological MalignancyMelanomaThyroid Cancer, Papillary+9 more
Cancer Research UK 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT02867592
What this trial is testing

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Who this might be right for
Adrenal Cortical CarcinomaAlveolar Soft Part SarcomaCentral Nervous System Neoplasm+41 more
National Cancer Institute (NCI) 109
Large-scale testing (Phase 3)Looking for participantsNCT05770544
What this trial is testing

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

Who this might be right for
Haematological MalignancyMalignancyMalignant Neoplasm+8 more
Cancer Research UK 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05715281
What this trial is testing

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Who this might be right for
Advanced Rare Malignant Solid NeoplasmRare Malignant Solid NeoplasmRefractory Rare Malignant Solid Neoplasm
National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT03074513
What this trial is testing

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Who this might be right for
Appendix AdenocarcinomaHuman Papillomavirus-Related Anal Squamous Cell CarcinomaHuman Papillomavirus-Related Cervical Squamous Cell Carcinoma+18 more
M.D. Anderson Cancer Center 133
Testing effectiveness (Phase 2)Active Not RecruitingNCT02721732
What this trial is testing

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

Who this might be right for
Advanced Malignant Solid NeoplasmCarcinoma of Unknown PrimaryMetastatic Adrenal Gland Pheochromocytoma+16 more
M.D. Anderson Cancer Center 157
Testing effectiveness (Phase 2)Looking for participantsNCT07070232
What this trial is testing

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Who this might be right for
Advanced Solid Tumor
BioNTech SE 1,438
Testing effectiveness (Phase 2)Active Not RecruitingNCT06303167
What this trial is testing

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 19
Large-scale testing (Phase 3)Looking for participantsNCT05722886
What this trial is testing

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Who this might be right for
Haematological MalignancySolid Tumour
Cancer Research UK 825
Large-scale testing (Phase 3)Looking for participantsNCT06988475
What this trial is testing

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

Who this might be right for
Solid TumourHaematological MalignancyMalignant Neoplasm+8 more
Cancer Research UK 30
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Large-scale testing (Phase 3)Looking for participantsNCT05770102
What this trial is testing

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Who this might be right for
MalignancyMalignant NeoplasmLymphoproliferative Disorders+7 more
Cancer Research UK 30
Next Page